Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
mercredi, novembre 18
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
OS Therapies Inc
OSTX
AMEX
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$0.8880
0.14
19.23%
Dern. MÀJ: Nov 18, 11:33 AM
Get Report
Aperçu
Actualités
Graphiques
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Rapport sur les stocks
OS Therapies Financials
OS Therapies (OSTX) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
Earnings Scheduled For May 18, 2026
Benzinga Insights
PRO
OS Therapies Q1 EPS $(0.27) Misses $(0.18) Estimate
OS Therapies (AMEX:OSTX) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.18) by 50 percent. This is a 50 percent decrease over losses of $(0.18) per share from the same
Benzinga Newsdesk
PRO
OS Therapies Q4 EPS $(0.41) Misses $(0.13) Estimate
OS Therapies (AMEX:OSTX) reported quarterly losses of $(0.41) per share which missed the analyst consensus estimate of $(0.13) by 228 percent. This is a 70.83 percent decrease over losses of $(0.24) per share from the
Benzinga Newsdesk
PRO
OS Therapies Q3 EPS $(0.21) Misses $(0.13) Estimate
Benzinga Newsdesk
PRO
OS Therapies Q2 EPS $(0.19) Misses $(0.12) Estimate
OS Therapies (AMEX:OSTX) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $(0.12) by 65.22 percent. This is a 26.92 percent increase over losses of $(0.26) per share from the
Benzinga Newsdesk
Earnings Outlook For OS Therapies
Benzinga Insights